SynthesisPloS one2014
Effect of HDL-raising drugs on cardiovascular outcomes: a systematic review and meta-regression.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Cross-ancestry analyses of Chinese and European populations reveal insights into the genetic architecture and disease implication of metabolites.Cell genomics · 2025Pooled it
- Defining a minimal clinically meaningful difference in 12-month estimated glomerular filtration rate for clinical trials in deceased donor kidney transplantation.Clinical transplantation · 2021Pooled it
- Twelve-Week Safety and Potential Lipid Control Efficacy of Coffee Cherry Pulp Juice Concentrate in Healthy Volunteers.Nutrients · 2023Trial
- Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study.Lipids in health and disease · 2020Trial
- High-density lipoprotein cholesterol: function, dysfunction, and clinical implications.American journal of preventive cardiology · 2026Article
- HDL-Associated Specific Paraoxonase-1 Activity Is Linked to Atherogenic Lipoprotein Measures in a High Cardiovascular Risk Population: A Cross-Sectional Study.Antioxidants (Basel, Switzerland) · 2026Article
- Apolipoprotein E-Containing High-Density Lipoprotein is Independently Associated with Atherosclerotic Plaque Progression.Journal of atherosclerosis and thrombosis · 2026Article
- Genetic testing in individuals with extreme HDL-C levels: Diagnostic yield and clinical implications from the Tromsø Study.PloS one · 2026Article
- Effects of HDL Structure and Function in Peripheral Artery Disease.Biomolecules · 2025Article
- Elucidating the causal role of age of menarche, adiposity, lipid fractions, and blood pressure upon cardiovascular disease: a multivariable Mendelian randomization study.Journal of human hypertension · 2025Article
- Article
- HDL meets triglyceride.Journal of lipid research · 2025Article
- Article
- HDL-C criterion of the metabolic syndrome and future diabetes and atherosclerosis in midlife women: The SWAN Study.American journal of preventive cardiology · 2024Article
- A novel splicing variant in ABCA1 in the first reported Hong Kong Chinese patient with high-density lipoprotein deficiency.Endocrinology, diabetes & metabolism case reports · 2024Article
- The association of the platelet/high-density lipoprotein cholesterol ratio with self-reported stroke and cardiovascular mortality: a population-based observational study.Lipids in health and disease · 2024Observational
- Association between biomarkers of inflammation and dyslipidemia in drug resistant tuberculosis in Uganda.Lipids in health and disease · 2024Article
- Foundations of Lifestyle Medicine and its Evolution.Mayo Clinic proceedings. Innovations, quality & outcomes · 2024Article
- Does Elevated High-Density Lipoprotein Cholesterol Protect Against Cardiovascular Disease?The Journal of clinical endocrinology and metabolism · 2024Article
- Association of non-high-density lipoprotein to high-density lipoprotein ratio (NHHR) with prognosis in cancer survivors: a population-based study in the United States.Frontiers in nutrition · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSubstantial residual cardiovascular risk remains after optimal LDL lowering in patients of established coronary artery disease. A number of therapeutic agents that raise HDL-C have been tested in clinical trials to cover this risk. However, the results of clinical trials are conflicting.
objectivesTo determine whether raising HDL-C with pharmacologic therapies translates into beneficial cardiovascular outcomes and to find out if this change was proportional to the percentage change in HDL levels.
methodsElectronic and printed sources were searched up to August, 2013 for randomised controlled trials (RCTs) using at least one of the HDL raising therapies for secondary prevention of adverse cardiovascular events over optimal LDL levels. Data from eligible studies were pooled for the following outcomes: all cause mortality, cardiovascular disease mortality, hospitalization for unstable angina, non-fatal myocardial infarction, coronary revascularization and ischemic stroke. Mantel Haensnzel fixed effect model was used preferentially. Meta-regression was done to see the correlation of change in HDL levels and cardiovascular outcomes. Pooled odds ratios with 95% confidence interval (CI) were calculated.
resultsA total of 12 RCTs including 26,858 patients with follow up period ranging from 1 year to 6.2 years were included in the analysis. Pooled analysis showed no significant difference in all-cause mortality between the treatment and control group (Pooled OR 1.07; 95% CI 0.98-1.16, p = 0.15). No significant difference was found between the groups for any of the secondary outcomes. Similarly no correlation was seen between percentage change in HDL and adverse cardiovascular outcomes on meta-regression analysis.
conclusionIncreasing HDL levels via pharmacological manipulation beyond optimal lipid lowering therapy for secondary prevention is not beneficial.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.